Duchenne muscular dystrophy (DMD) is a genetic disease that leads to muscle degeneration and loss of ambulation for which there are no available therapies. Preclinical research in animal models is thus crucial to develop new treatments, but predictive markers for disease progression and outcome, which would help assess the effects of a therapy, are currently limited. In this context, canine models of DMD – such as the Golden Retriever muscular dystrophy (GRMD) dog – are particularly valuable, as they share several similarities with the human disease, including a high inter-individual clinical heterogeneity. Here, Stéphane Blot, Gillian Butler-Browne and colleagues assessed motor dysfunction in GRMD dogs at 2 months of age, the time of clinical onset in this species. A few weeks later, one third of the animals displayed loss of ambulation, the most severe disease-related symptom. The authors found that the levels of circulating lymphocytes in the blood as well as the gait speed and stride frequency strongly correlated with the severity and progression of the disease in the animals. Notably, the same parameters have been shown to be predictive of loss of ambulation in DMD-affected individuals. Therefore, these three non-invasive biomarkers could immediately be used to screen experimental animals before testing specific therapeutic compounds. This approach not only will improve the reliability of preclinical trials performed on these large animals but will also hopefully speed up the discovery of new potential treatments for DMD. Page 1253
A promising preclinical test for DMD in dog models
- Split-screen
- Views Icon Views
-
Article Versions Icon
Versions
- Version of Record 01 November 2014
- Share Icon Share
-
Tools Icon
Tools
- Search Site
A promising preclinical test for DMD in dog models. Dis Model Mech 1 November 2014; 7 (11): e1102. doi:
Download citation file:
Advertisement
Cited by
Sex matters in preclinical research
DMM calls for improved inclusion, analysis and reporting of sex as a biological variable in preclinical animal modelling research. Read the full Editorial by Monica J. Justice.
Subject collection: Building advocacy into research
DMM’s new series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Travelling Fellowships for early-career researchers
DMM and its sister journals offer Travelling Fellowships of up to £3,000 to graduate students and post-doctoral researchers wishing to make collaborative visits to other laboratories. Find out more about our Travelling Fellowships and read stories from previous grant recipients.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
The Forest of Biologists
Our Publisher Claire Moulton recently visited the two Woodland Trust UK sites where we are planting new native trees for published Research and Review papers and protecting ancient woodland on behalf of our peer reviewers.
Other journals from
The Company of Biologists